CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Go back to CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia| (NASDAQ: CRVO) | Delayed: 2.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.86 | 52 Week High | $ | |||
| Open | $2.86 | 52 Week Low | $ | |||
| Day High | $2.86 | P/E | N/A | |||
| Day Low | $2.86 | EPS | $ | |||
| Volume | 2,630 | |||||
